Athira Pharma Files 8-K on Security Holder Rights
Ticker: LONA · Form: 8-K · Filed: Sep 11, 2025 · CIK: 1620463
| Field | Detail |
|---|---|
| Company | Athira Pharma, INC. (LONA) |
| Form Type | 8-K |
| Filed Date | Sep 11, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, filing, rights
Related Tickers: ATHA
TL;DR
Athira Pharma (ATHA) filed an 8-K today, watch for changes to shareholder rights and corporate docs.
AI Summary
Athira Pharma, Inc. filed an 8-K on September 10, 2025, reporting material modifications to the rights of security holders and amendments to its articles of incorporation or bylaws. The filing also includes financial statements and exhibits. The company, formerly known as M3 Biotechnology, Inc., is based in Bothell, WA.
Why It Matters
This 8-K filing indicates potential changes affecting Athira Pharma's shareholders and corporate structure, requiring investor attention.
Risk Assessment
Risk Level: medium — Filings related to modifications of security holder rights and corporate amendments can signal significant changes that may impact stock value.
Key Numbers
- 001-39503 — SEC File Number (Identifies the company's filing history with the SEC.)
- 45-3368487 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Athira Pharma, Inc. (company) — Registrant
- M3 Biotechnology, Inc. (company) — Former company name
- September 10, 2025 (date) — Date of earliest event reported
- Bothell, WA (location) — Principal executive offices
FAQ
What specific material modifications to the rights of security holders are being reported?
The filing indicates 'Material Modifications to Rights of Security Holders' as an item information, but the specific details of these modifications are not provided in the excerpt.
What amendments to the articles of incorporation or bylaws are being reported?
The filing lists 'Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year' as an item information, but the specific amendments are not detailed in the provided text.
When was Athira Pharma, Inc. formerly known as M3 Biotechnology, Inc.?
The company's name change from M3 Biotechnology, Inc. to Athira Pharma, Inc. occurred on September 24, 2014.
What is Athira Pharma's principal executive office address?
Athira Pharma's principal executive offices are located at 18706 North Creek Parkway, Suite 104, Bothell, WA 98011.
What is the SIC code for Athira Pharma, Inc.?
The Standard Industrial Classification (SIC) code for Athira Pharma, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 946 words · 4 min read · ~3 pages · Grade level 10.8 · Accepted 2025-09-11 09:00:30
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ATHA The Nasdaq
Filing Documents
- atha-20250910.htm (8-K) — 59KB
- atha-ex3_1.htm (EX-3.1) — 18KB
- atha-ex99_1.htm (EX-99.1) — 16KB
- img247042425_0.jpg (GRAPHIC) — 58KB
- 0000950170-25-114093.txt ( ) — 293KB
- atha-20250910.xsd (EX-101.SCH) — 27KB
- atha-20250910_htm.xml (XML) — 5KB
03 Material Modification to Rights of Security Holders
Item 3.03 Material Modification to Rights of Security Holders. To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference.
03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On September 10, 2025, the Company filed a certificate of amendment to the Company's Amended and Restated Certificate of Incorporation (the "Certificate of Amendment"), with the Secretary of State of the State of Delaware to effect a 10-for-1 reverse stock split of the shares of the Company's common stock, par value $0.0001 per share, effective as of 5:00 p.m., Eastern Time, on September 17, 2025 (the "Reverse Stock Split"). The total number of authorized shares of the Company's common stock will be reduced from 900,000,000 to 90,000,000 and the total number of authorized shares of the Company's capital stock will be reduced from 1,000,000,000 to 190,000,000. The common stock is expected to begin trading on a post-split basis on The Nasdaq Capital Market ("Nasdaq") as of the open of trading on September 18, 2025, and the trading symbol will continue to be "ATHA". In connection with the Reverse Stock Split, the CUSIP number for the common stock will be changed to 04746L203. As previously disclosed, the Company's stockholders approved the Certificate of Amendment to effect the Reverse Stock Split at the Annual Meeting of Stockholders held on May 29, 2025 (the "Annual Meeting"). Following the Annual Meeting, the Board determined to effect the Reverse Stock Split at a ratio of 10-for-1. As a result of the Reverse Stock Split, every ten (10) shares of the Company's issued and outstanding common stock will be automatically combined into one issued and outstanding share of common stock, without any change in the par value per share. Any fractional shares that would otherwise be issuable as a result of the Reverse Stock Split will be paid out in cash. Proportional adjustments will be made to the number of shares of common stock issuable upon the exercise or settlement of the Company's outstanding options and restricted stock units, and the number of shares authorized and reserved for i
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Athira Pharma, Inc. 99.1 Athira Pharma, Inc. press release dated September 11, 2025. 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Athira Pharma, Inc. Date: September 11, 2025 By: /s/ Mark Litton Mark Litton President and Chief Executive Officer